We are international
• meetings TEXT SIZE   

Tokyo Patient & Family Seminar - November 2, 2003
Sun, Nov 02, 2003

Seiryo Kaikan
2-16-2, Nagata-cho, Chiyoda-ku
Tokyo 100-0014 (adjacent to the metropolitan Hibiya senior high school)

Link to IMF Tokyo Seminar Announcement

9:00 to 9:10 Opening Remarks
Susie Novis
President, International Myeloma Foundation
9:20 to 9:40 Standard Treatment of Multiple Myeloma in the USA
Brian G.M. Durie, M.D.
Cedars-Sinai Comprehensive Cancer Center
9:50 to 10:10 Standard Treatment of Multiple Myeloma in Japan
Shuji Ozaki, M.D.
Tokushima University Hospital
Division of Transfusion Medicine
First Department of Internal Medicine
10:10 to 10:30 Break
10:30 to 10:50

Anticancer Drug Treatment: Chemotherapy and Thalidomide Therapies
Yutaka Hattori M.D., Ph.D.
Division of Hematology, Department of Medicine
Keio University School of Medicine

11:00 to 11:20

Transplant Treatment: Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation
Chihiro Shimazaki, M.D.
Division of Hematology
Kyoto Prefectural University of Medicine

11:20-13:00 Lunch Break
13:00 to 13:20

Treatment of Hypercalcaemia and Osteolytic Lesion in Multiple Myeloma
Kiyoshi Nakatsuka, M.D.
Department of Metabolism, Endocrinology & Molecular Medicine
Osaka City University Graduate School of Medicine

13:30-13:50 Orthopedic Treatment of Bone Lesion
Shinjiro Takata, M.D., Ph.D.
Department of Orthopedics
The University of Tokushima School of Medicine
13:50-14:10 Break
14:10 to 14:30 What Clinical Trial Participants Need to Know
Yasuo Ohashi, Ph.D.
Biostatistics/Epidemiology and Preventive Health Sciences
School of Health Sciences and Nursing
University of Tokyo
Japan Clinical Research Support Unit
14:40 to 15:00

Clinical Trials of Thalidomide Therapy in Japan and Their Safety Measures
Naokata Shimizu, M.D., Ph.D.
The Organization for Pharmaceutical Safety and Research (OPSR/Kiko)
Teikyo University Medical Department

15:00 to 15:20 Break
15:20 to 16:10

Recent Progress in Reduced-Intensity Stem-Cell Transplantation (RIST)
Masahiro Kami, M.D.
National Cancer Central Hospital
Stem Cell Transplantation Unit

15:50 to 15:40 New Medicine: Velcade, Revimid, Trisenox, etc.
Brian G.M. Durie, M.D.
16:10 to 16:50 Questions and Answers
16:50 to 17:00 Closing Remarks
Susie Novis
President, International Myeloma Foundation
17:00 to 19:00 Reception

At the same time as the lectures, consultation booths will be open for participants to meet with experts:

  • Medical consultation booths for second opinion applicants
  • Clinical trial consultation booths for prospective participants
  • IMF-Japan booth to provide information and to help enroll applicants in support groups

Link to IMF Tokyo Seminar Announcement


International Myeloma Foundation
Tokyo Representative Office
OKUBO, Ikumi (Ms)
65-28 Midoricho, Hachioji
Tokyo, 193-0932 Japan
e-mail: okuboikumi@nifty.com
Phone: +81(426)24-9848
Fax: +81(426)24-9864